Immunogenicity, clinical efficacy, and safety of the sinopharm (BBIBP-CorV) SARS-CoV-2 vaccine among people with multiple sclerosis receiving disease-modifying therapies: a prospective cohort study
BBIBP-CorV appeared to be well tolerated in PwMS, with promising clinical efficacy. However, a suboptimal humoral response was observed in PwMS receiving fingolimod and anti-CD20s. Future research should investigate the relationship between humoral responses and the frequency and severity of COVID-19 infection across various DMTs.
Authors
- Mehdi Azizmohammad Looha (ORCID: https://orcid.org/0000-0002-0700-1431)
- Mobina Amanollahi
- Mohammad Hossein Harirchian (ORCID: https://orcid.org/0000-0002-1158-8677)
- Kiana Amani
- Mohammad Abdollahı (ORCID: https://orcid.org/0000-0003-0123-1209)
- Zahra Ebadi (ORCID: https://orcid.org/0000-0003-2302-3574)
- Fatemeh Nobahari
- M Beladi Mousavi (ORCID: https://orcid.org/0009-0005-9568-0612)
- Bahareh Pourghaz
- Melika Jameie
Institutions
- Imam Khomeini Hospital (IR)
- Shahid Beheshti University of Medical Sciences (IR)
- Tehran University of Medical Sciences (IR)
Publication Details
- Journal
- BMC Neurology
- Published
- 2024-08-20
- DOI
- https://doi.org/10.1186/s12883-024-03793-y
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00